Literature DB >> 19412697

[Third generation beta-blockers: current state of research on vasodilating beta-blockers].

Dennis Ladage1, Christian Reidenbach, Albert Lichtenthal, Robert Schwinger, Klara Brixius.   

Abstract

Nebivolol (Nomexor) is a third generation, vasodilating beta-blocker with a high beta(1)-adrenoceptor selectivity. Nebivolol acts as an agonist at the beta(3) adrenoceptor as well as the estrogen receptor thereby releasing nitric oxide in blood vessels via eNOS. Pleiotropic effects of nebivolol furthermore include a positive influence on cholesterol and triglycerides and a decrease in thrombocyte activity. Nebivolol is recommended in the guidelines of the European cardiac society (ESC) for patients with metabolic syndrome. Nebivolol's main properties in combination with its broad range of beneficial pleiotropic effects allow it to be clearly distinguished from other second and third generation beta-blockers.

Entities:  

Mesh：

Substances：

Year:  2009        PMID： 19412697     DOI： 10.1007/s10354-009-0650-3

Source DB:  PubMed          Journal:  Wien Med Wochenschr        ISSN： 0043-5341


  26 in total

1.  Endothelial beta3-adrenoreceptors mediate nitric oxide-dependent vasorelaxation of coronary microvessels in response to the third-generation beta-blocker nebivolol.

Authors:  Chantal Dessy; Julie Saliez; Philippe Ghisdal; Géraldine Daneau; Irina I Lobysheva; Françoise Frérart; Catharina Belge; Karima Jnaoui; Philippe Noirhomme; Olivier Feron; Jean-Luc Balligand
Journal:  Circulation       Date:  2005-08-23       Impact factor: 29.690

Review 2.  The role of the new beta-blockers in treating cardiovascular disease.

Authors:  Michael A Weber
Journal:  Am J Hypertens       Date:  2005-12       Impact factor: 2.689

3.  Influence of nebivolol and enalapril on metabolic parameters and arterial stiffness in hypertensive type 2 diabetic patients.

Authors:  Thomas Kaiser; Tim Heise; Leszek Nosek; Uta Eckers; Peter T Sawicki
Journal:  J Hypertens       Date:  2006-07       Impact factor: 4.844

Review 4.  Biosynthesis and metabolism of endothelium-derived nitric oxide.

Authors:  L J Ignarro
Journal:  Annu Rev Pharmacol Toxicol       Date:  1990       Impact factor: 13.820

5.  Effects of nebivolol on left ventricular function in elderly patients with chronic heart failure: results of the ENECA study.

Authors:  Istvan Edes; Zbigniew Gasior; Krystian Wita
Journal:  Eur J Heart Fail       Date:  2005-06       Impact factor: 15.534

6.  Beta-blockers of the third generation inhibit endothelin-1 liberation, mRNA production and proliferation of human coronary smooth muscle and endothelial cells.

Authors:  B R Brehm; D Bertsch; J von Fallois; S C Wolf
Journal:  J Cardiovasc Pharmacol       Date:  2000-11       Impact factor: 3.105

7.  [Nebivolol, a third generation beta blocker: the modern treatment of hypertension. Results of a multicentric observational study].

Authors:  J von Fallois; H D Faülhaber
Journal:  Fortschr Med Orig       Date:  2000-07-27

8.  Randomized trial to determine the effect of nebivolol on mortality and cardiovascular hospital admission in elderly patients with heart failure (SENIORS).

Authors:  Marcus D Flather; Marcelo C Shibata; Andrew J S Coats; Dirk J Van Veldhuisen; Aleksandr Parkhomenko; Joszef Borbola; Alain Cohen-Solal; Dan Dumitrascu; Roberto Ferrari; Philippe Lechat; Jordi Soler-Soler; Luigi Tavazzi; Lenka Spinarova; Jiri Toman; Michael Böhm; Stefan D Anker; Simon G Thompson; Philip A Poole-Wilson
Journal:  Eur Heart J       Date:  2005-01-09       Impact factor: 29.983

9.  Effects of nebivolol on proliferation and apoptosis of human coronary artery smooth muscle and endothelial cells.

Authors:  B R Brehm; S C Wolf; D Bertsch; M Klaussner; S Wesselborg; S Schüler; K Schulze-Osthoff
Journal:  Cardiovasc Res       Date:  2001-02-01       Impact factor: 10.787

10.  Efficacy and tolerability profile of nebivolol vs atenolol in mild-to-moderate essential hypertension: results of a double-blind randomized multicentre trial.

Authors:  Guido Grassi; Fosca Quarti Trevano; Annalisa Facchini; Torakis Toutouzas; Bernard Chanu; Giuseppe Mancia
Journal:  Blood Press Suppl       Date:  2003-12
View more
  1 in total

Review 1.  Differential Metabolic Effects of Beta-Blockers: an Updated Systematic Review of Nebivolol.

Authors:  Maria Marketou; Yashaswi Gupta; Shashank Jain; Panos Vardas
Journal:  Curr Hypertens Rep       Date:  2017-03       Impact factor: 5.369
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.